Registration Reopened for the FDA Virtual Workshop Entitled “Roadmap to 2030 for New Drug Evaluation in Older Adults” on March 23, 2021

Registration Reopened! Roadmap to 2030 for New Drug Evaluation in Older Adults Workshop

Registration Reopened for the FDA Virtual Workshop Entitled "Roadmap to 2030 for New Drug Evaluation in Older Adults" on March 23, 2021 Due to high interest, the U.S. Food and Drug Administration (FDA) has reopened registration for a virtual public workshop entitled "Roadmap to 2030 for New Drug Evaluation in Older Adults" on March 23, 2021. This workshop will bring together stakeholders from academia, industry, and regulatory agencies in a virtual setting to discuss the current status of inclusion of older adults in clinical trials and strategies to ensure the safe and effective use of drugs in this population.   Americans are leading longer and healthier lives than ever before, but older adults often consume multiple prescription medications and may be under-represented in pre-marketing drug evaluations, leading to insufficient data on the safety and effectiveness of medications for this population. Initial pharmacokinetic/ pharmacodynamic studies and later clinical trials to evaluate age-related changes often do not include typical older adults who have multiple chronic conditions and take multiple medications. This can lead to insufficient data on the safety and effectiveness of medications in this population at the time of marketing approval. Data on the safety and effectiveness for new medications likely to be prescribed in typical older adults, especially those at the oldest end of the age span, are critically needed. This workshop will discuss methods to ensure that inclusion of older adults in drug evaluations is representative of the target population for treatment and will also discuss potential strategies to ensure safe and effective drug use in older adults. Workshop Objectives: Review the current regulations and draft guidances for drug evaluation and labeling of medications for older adults Review the current data on the inclusion of older adults in clinical trials in selected key therapeutic areas Identify the gaps in regulations, guidances, and inclusion of older adults in data collection Explore approaches to close the existing gaps The date, time, and location of the workshop are as follows: Date:                Tuesday, March 23, 2021 Time:               10:00 am - 4:30 pm (EST) Location:         This is a virtual public workshop. Meeting Information and Registration: This workshop is open to the public with no cost to attend, but registration is required. To register, please visit https://www.eventbrite.com/e/fda-roadmap-to-2030-for-new-drug-evaluation-in-older-adults-tickets-137460709683 If you have any additional questions about this workshop, please contact OCPWorkshops@fda.hhs.gov. The Office of Clinical Pharmacology (OCP) is pleased to offer the e-mail subscription service Clinical Pharmacology Corner. This is a free service from FDA to provide occasional updates from OCP regarding newly approved therapies, new regulatory and scholarly publications, upcoming events and other items of interest. Subscribe today at https://public.govdelivery.com/accounts/USFDA/subscriber/topics and select Clinical Pharmacology Corner under Drugs. We always welcome your thoughts regarding the format, content, and utility of this communication. Comments may be sent via email to ocp@fda.hhs.gov. This communication was prepared by the Office of Clinical Pharmacology, Office of Translational Sciences, CDER, FDA.

Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA